The Obesity ETF (SLIM)

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show early efficacy in BMI and hyperphagia reduction, though limited by small sample size and responder heterogeneity. RYTM's HO sNDA PDUFA was delayed to March 2026 for additional FDA analysis, but I remain optimistic on approval with some risk to pediatric labeling.

Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug into registrational testing for Prader-Willi.

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.

The company said some patients had dropped out of the trial because they felt they were losing too much weight.

Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouraging developments for their latest obesity drugs.

Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial.

NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("CANYON-1"), with completion expected in summer 2026. CRB-913 is a highly peripherally restricted oral small molecule CB1 inverse agonist targeting chronic obesity management.

Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at 36 weeks with 240 mg, with no plateau and improved tolerability via titration from 2.5 mg. Key GPCR stock catalysts include a Type B End of Phase 2 FDA meeting in H1 2026 and potential phase 3 initiation mid-2026, targeting a large obesity market.

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.

Rhythm Pharmaceuticals, Inc. maintaining a Strong Buy rating, driven by IMCIVREE's growth and multiple late-stage expansion opportunities in rare genetic obesity indications. RYTM's IMCIVREE awaits FDA label expansion for acquired hypothalamic obesity, with the PDUFA date extended to March 20, 2026, after a major filed amendment. Upcoming Q4 2025 phase 2 data for IMCIVREE in Prader-Willi Syndrome and positive Bivamelagon results for acquired hypothalamic obesity offer additional catalysts and shots on goal.

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

NEW YORK--(BUSINESS WIRE)---- $LLY #GLP1--Ilant Health announced that it will offer employers direct contracting and transparent pricing of Eli Lilly and Company (Lilly) obesity management medicines. Employers working with Ilant Health will have the option of accessing obesity management medicines at a transparent and predictable price point starting in early 2026. Medications obtained through this collaboration will be fulfilled by a licensed mail-order pharmacy, supporting convenience, continuity, and a sea.

Denmark's seasonally adjusted gross domestic product grew by 2.3% in the third quarter, a preliminary reading from Statistics Denmark showed early Thursday. The main driver of growth was the pharmaceutical industry, the agency said.

SAN FRANCISCO and SUZHOU, China , Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met the primary endpoints and all key secondary endpoints. Innovent plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term.